Positive News SentimentPositive News OptimizeRx Stock Price, News & Analysis (NASDAQ:OPRX) $9.96 +0.45 (+4.73%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$9.46▼$10.0350-Day Range$7.06▼$10.0252-Week Range$6.92▼$20.55Volume235,431 shsAverage Volume170,592 shsMarket Capitalization$180.77 millionP/E RatioN/ADividend YieldN/APrice Target$15.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media OptimizeRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside56.6% Upside$15.60 Price TargetShort InterestBearish5.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.65) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsComputer And Technology Sector384th out of 592 stocksBusiness Services, Not Elsewhere Classified Industry64th out of 86 stocks 3.5 Analyst's Opinion Consensus RatingOptimizeRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.60, OptimizeRx has a forecasted upside of 56.6% from its current price of $9.96.Amount of Analyst CoverageOptimizeRx has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.08% of the outstanding shares of OptimizeRx have been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in OptimizeRx has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPRX. Previous Next 3.3 News and Social Media Coverage News SentimentOptimizeRx has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 1 news article for OptimizeRx this week, compared to 1 article on an average week.Search Interest3 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions77.82% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.65) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -12.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -12.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OptimizeRx Stock (NASDAQ:OPRX)OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.Read More OPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPRX Stock News HeadlinesNovember 21, 2023 | finance.yahoo.comWhy OptimizeRx Corp. (OPRX) Might be Well Poised for a SurgeNovember 20, 2023 | finance.yahoo.comHow Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%December 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 18, 2023 | morningstar.comOptimizeRx Corp OPRXNovember 14, 2023 | finance.yahoo.comIndustry Analysts Just Made A Massive Upgrade To Their OptimizeRx Corporation (NASDAQ:OPRX) Revenue ForecastsNovember 13, 2023 | finance.yahoo.comOptimizeRx Corporation (NASDAQ:OPRX) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on OptimizeRx (OPRX)November 6, 2023 | msn.comOptimizeRx beats Q3 top and bottom line estimates; initiates FY24 and updates FY23 outlookDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 6, 2023 | finance.yahoo.comOptimizeRx Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comOptimizeRx Corp (OPRX) Reports Q3 2023 Earnings, Raises 2023 Guidance and Introduces 2024 GuidanceNovember 4, 2023 | finance.yahoo.comInvestors in OptimizeRx (NASDAQ:OPRX) from three years ago are still down 60%, even after 11% gain this past weekNovember 3, 2023 | benzinga.comA Preview Of OptimizeRx's EarningsNovember 3, 2023 | msn.comOptimizeRx Q3 2023 Earnings PreviewOctober 30, 2023 | finance.yahoo.comOptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?October 25, 2023 | finance.yahoo.comOptimizeRx Announces Completion of Medicx Acquisition and Sets Third Quarter 2023 Conference Call for November 6, 2023, at 8:30 a.m. ETOctober 13, 2023 | markets.businessinsider.comOptimizeRx (OPRX) Receives a Buy from Lake StreetOctober 13, 2023 | finance.yahoo.comOptimizeRx Corp. (OPRX) Surges 13.0%: Is This an Indication of Further Gains?October 12, 2023 | markets.businessinsider.comOptimizeRx’s Acquisition of Medicx Health: A Strategic Move Towards Enhanced Patient Marketing and Significant GrowthOctober 12, 2023 | msn.comDigital Health Tech OptimizeRx's Acquisition of Medicx Health To Boost Earnings And Market Potential: AnalystOctober 12, 2023 | finanznachrichten.deOptimizeRx Corporation: OptimizeRx Announces Agreement to Acquire Medicx Health for $95 million to Expand its Omnichannel Reach to ConsumersOctober 12, 2023 | seekingalpha.comOptimizeRx to acquire Medicx Health for $95MOctober 8, 2023 | finance.yahoo.comShould You Investigate OptimizeRx Corporation (NASDAQ:OPRX) At US$7.29?September 26, 2023 | finance.yahoo.comOptimizeRx Unveils a Significant Enhancement to its Omni-channel Healthcare Engagement PlatformSeptember 21, 2023 | finance.yahoo.comAre OptimizeRx Corporation (NASDAQ:OPRX) Investors Paying Above The Intrinsic Value?August 24, 2023 | finance.yahoo.comOptimizeRx Expands AI Powered Omnichannel PlatformAugust 20, 2023 | finance.yahoo.comOptimizeRx Corporation (NASDAQ:OPRX) Analysts Just Trimmed Their Revenue Forecasts By 13%See More Headlines Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Business services, not elsewhere classified Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees109Year FoundedN/APrice Target and Rating Average Stock Price Target$15.60 High Stock Price Target$20.00 Low Stock Price Target$13.00 Potential Upside/Downside+56.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,440,000.00 Net Margins-21.88% Pretax Margin-21.88% Return on Equity-9.24% Return on Assets-8.71% Debt Debt-to-Equity RatioN/A Current Ratio11.35 Quick Ratio11.35 Sales & Book Value Annual Sales$62.45 million Price / Sales2.89 Cash FlowN/A Price / Cash FlowN/A Book Value$6.40 per share Price / Book1.56Miscellaneous Outstanding Shares18,150,000Free Float17,353,000Market Cap$180.77 million OptionableNot Optionable Beta1.05 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. William J. Febbo (Age 54)CEO & Director Comp: $694.4kMr. Edward Stelmakh C.M.A. (Age 57)M.B.A., CFO & COO Comp: $547.05kMr. Andrew Jacob D'SilvaSenior Vice President of Corporate FinanceMr. Todd Inman (Age 67)Chief Technology Officer Ms. Marion K Odence-Ford (Age 58)General Counsel & Chief Compliance Officer Comp: $428.12kMaira AlejandraMedia Relations ManagerMs. Sheryl KearneyHuman Resources ManagerMr. Terence J. Hamilton (Age 58)Senior Vice President of Pharma Comp: $441.63kDr. Doug Besch (Age 41)Chief Product Officer Ms. Theresa GrecoChief Commercial OfficerMore ExecutivesKey CompetitorsDHI GroupNYSE:DHXEdgioNASDAQ:EGIOZeroFoxNASDAQ:ZFOXMarchexNASDAQ:MCHXSteel ConnectNASDAQ:STCNView All CompetitorsInstitutional OwnershipConnors Investor Services Inc.Bought 4,000 shares on 11/22/2023Ownership: 0.124%Tudor Investment Corp Et AlSold 18,346 shares on 11/16/2023Ownership: 0.150%Avenir CorpSold 74,111 shares on 11/15/2023Ownership: 1.848%GSA Capital Partners LLPBought 1,816 shares on 11/15/2023Ownership: 0.385%AQR Capital Management LLCBought 12,355 shares on 11/15/2023Ownership: 0.074%View All Institutional Transactions OPRX Stock Analysis - Frequently Asked Questions Should I buy or sell OptimizeRx stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks. What is OptimizeRx's stock price target for 2024? 8 Wall Street research analysts have issued 1-year price targets for OptimizeRx's stock. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's share price to reach $15.60 in the next twelve months. This suggests a possible upside of 56.6% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts. How have OPRX shares performed in 2023? OptimizeRx's stock was trading at $16.80 at the beginning of 2023. Since then, OPRX stock has decreased by 40.7% and is now trading at $9.96. View the best growth stocks for 2023 here. When is OptimizeRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 13th 2024. View our OPRX earnings forecast. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) posted its earnings results on Monday, November, 6th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The company had revenue of $16.33 million for the quarter, compared to analysts' expectations of $15.07 million. OptimizeRx had a negative trailing twelve-month return on equity of 9.24% and a negative net margin of 21.88%. What ETFs hold OptimizeRx's stock? ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD).Global X Telemedicine & Digital Health ETF (EDOC). What guidance has OptimizeRx issued on next quarter's earnings? OptimizeRx updated its FY 2023 earnings guidance on Monday, November, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $63.00 million-$65.00 million, compared to the consensus revenue estimate of $60.51 million. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN). Who are OptimizeRx's major shareholders? OptimizeRx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Blair William & Co. IL (5.03%), AWM Investment Company Inc. (4.70%), Kennedy Capital Management LLC (3.34%), Rice Hall James & Associates LLC (2.33%), Jacob Asset Management of New York LLC (2.23%) and Federated Hermes Inc. (2.09%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:OPRX) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.